Astrazeneca

FromAstraZeneca ([email protected])
Sent withMailchimp
Subject (123)Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
Preheader (123)Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
Typography
Arial
Colors
Text Analysis
Body Words131
Subject Words17
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px752 px
X-Spam Score1.0
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeOvernight

Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer

Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer